I kliniske undersøgelser blev topotecanbehandlingen stoppet, hvis dosis var blevet reduceret til 1, 0 mg/ m2 og yderligere reduktion af dosis var nødvendig for at håndtere bivirkninger.
In clinical trials, topotecan was discontinued if the dose had been reduced to 1.0 mg/ m2 and a further dose reduction was required to manage adverse effects.